Sunshine Biopharma, Inc (CIK: 0001402328) EDGAR, Information, Filings... CompaniesBIO.Com

Sunshine Biopharma, Inc

Mailing address
6500 TRANS-CANADA HIGHWAY, 4TH FLOOR, POINTE-CLAIRE, Colorado, H9R 0A5
Phone
514-426-6161
State location
A8
State of incorporation
Colorado
Fiscal year end
December 31
SIC
8731 - (CF Office: Office of Trade & Services) SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Filings
N/A

Sunshine Biopharma, Inc (CIK: 0001402328) is an American company incorporated in the state of A8. Head office is located at 6500 TRANS-CANADA HIGHWAY, 4TH FLOOR, POINTE-CLAIRE, A8, H9R 0A5. Work in the industry 8731 - (CF Office: Office of Trade & Services) SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH. Sunshine Biopharma, Inc is a public company and trade via Over-The-Counter (OTC).

Old names:

Mountain West Business Solutions, Inc from 2007-05-Nov to 2009-02-Nov
mountain west business solutions,inc from 2007-19-Oct to 2007-19-Oct
mountain state business solutions,inc from 2007-25-May to 2007-25-May

Owner	Filings	Transaction Date	Type of Owner
Chamoun Malek	0001951769	Oct-20-2022	10 percent owner
NATAN DAVID	0001253108	Feb-10-2022	director
Keller Andrew Mark	0001909593	Feb-10-2022	director
TELSEY ANDREW I	0001103152	Oct-31-2021	director
Kish James Daniel	0001895995	Oct-31-2021	director
Kiderchah Rabi	0001896715	Oct-31-2021	director
Advanomics Corp	0001681176	Jul-08-2016	10 percent owner
MERZOUKI ABDERRAZZAK	0001636418	Feb-20-2015	director, officer: Chief Operating Officer
Slilaty Steve N.	0001474684	Oct-15-2009	director, 10 percent owner, officer: CEO and President
Sebaaly Camille	0001474695	Oct-15-2009	director, officer: CFO and Secretary
Di Turi Michele	0001474699	Oct-15-2009	director, officer: Chief Operating Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Sunshine Biopharma, Inc

Filings	Format	Description	Filed/Effective	File/Film Number
8-K	Document	Current report filing Acc-no: 0001683168-25-009103 (34 Act) Size: KB	Dec-12-2025	001-41282 251568075
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001683168-25-008328 (34 Act) Size: KB	Nov-13-2025	001-41282 251478428
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0001683168-25-007749 (34 Act) Size: KB	Oct-23-2025	001-41282 251413686
DEF 14A	Document	Definitive proxy statements Acc-no: 0001683168-25-007747 (34 Act) Size: KB	Oct-23-2025	001-41282 251413682
8-K	Document	Current report filing Acc-no: 0001683168-25-007338 (34 Act) Size: KB	Sep-30-2025	001-41282 251360430
SCHEDULE 13G/A	Document	Acc-no: 0002000324-25-002749 (34 Act) Size: KB	Aug-14-2025	005-85054 251215365
EFFECT	Document	Acc-no: 9999999995-25-002587 (33 Act) Size: KB	Aug-12-2025	333-289230 251208762
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001683168-25-005981 (34 Act) Size: KB	Aug-12-2025	001-41282 251207625
424B3	Document	Prospectus filed pursuant to Rule 424(b)(3) Acc-no: 0001683168-25-005978 (33 Act) Size: KB	Aug-12-2025	333-289230 251207479
RW	Document	Registration Withdrawal Request Acc-no: 0001683168-25-005976 (NE Act) Size: KB	Aug-12-2025	333-276817 251207445
UPLOAD	Document	Acc-no: 0000000000-25-008396 ( Act) Size: KB	Aug-11-2025	333-289230
CORRESP	Document	A correspondence can be sent as a document with another submission type or can be sent as a separate submission. Acc-no: 0001683168-25-005883 ( Act) Size: KB	Aug-11-2025
S-1	Document	General form of registration statement for all companies including face-amount certificate companies Acc-no: 0001683168-25-005644 (33 Act) Size: KB	Aug-05-2025	333-289230 251181814
POS AM	Document	Post-effective amendment to a registration statement that is not immediately effective upon filing Acc-no: 0001683168-25-005404 (33 Act) Size: KB	Jul-25-2025	333-276817 251151713
SCHEDULE 13G/A	Document	Acc-no: 0000921895-25-001755 (34 Act) Size: KB	Jun-12-2025	005-85054 251044498
SCHEDULE 13G	Document	Acc-no: 0001213900-25-047357 (34 Act) Size: KB	May-23-2025	005-85054 25982540
8-K	Document	Current report filing Acc-no: 0001683168-25-003838 (34 Act) Size: KB	May-19-2025	001-41282 25964962
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001683168-25-003701 (34 Act) Size: KB	May-15-2025	001-41282 25952751
SCHEDULE 13G	Document	Acc-no: 0000921895-25-001064 (34 Act) Size: KB	Apr-11-2025	005-85054 25832902
8-K	Document	Current report filing Acc-no: 0001683168-25-002245 (34 Act) Size: KB	Apr-03-2025	001-41282 25808156

Recent 20 filings. View all Sunshine Biopharma, Inc filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Sunshine Biopharma, Inc overview
Sunshine Biopharma, Inc job
Sunshine Biopharma, Inc stock
Sunshine Biopharma, Inc ownership
Sunshine Biopharma, Inc CEO
Sunshine Biopharma, Inc documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.